Literature DB >> 19454068

Breast pain.

Nigel J Bundred1.   

Abstract

INTRODUCTION: Breast pain may be cyclical (worse before a period) or non-cyclical, originating from the breast or the chest wall, and occurs at some time in 70% of women. Cyclical breast pain resolves spontaneously in 20-30% of women, but tends to recur in 60% of women. Non-cyclical pain responds poorly to treatment but tends to resolve spontaneously in half of women. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments for breast pain? We searched: Medline, Embase, The Cochrane Library and other important databases up to January 2006 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 22 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: a low-fat diet, antibiotics, bromocriptine, danazol, diuretics, evening primrose oil, gestrinone, gonadorelin analogues, hormone replacement therapy, lisuride, progestogens, pyridoxine, tamoxifen, tibolone, topical non-steroidal anti-inflammatory drugs, toremifene, and vitamin E.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 19454068      PMCID: PMC2943772     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  25 in total

1.  European randomized, multicenter study of goserelin (Zoladex) in the management of mastalgia.

Authors:  Robert E Mansel; Amit Goyal; Paul Preece; Sam Leinster; Paul R Maddox; Christopher Gateley; Ernst Kubista; Dietrich von Fournier
Journal:  Am J Obstet Gynecol       Date:  2004-12       Impact factor: 8.661

2.  [Clinical efficacy of tamoxifen in the treatment of premenstrual mastodynia].

Authors:  R Grio; A Cellura; R Geranio; M Porpiglia; R Piacentino
Journal:  Minerva Ginecol       Date:  1998-03

3.  Evening primrose oil and fish oil for severe chronic mastalgia: a randomized, double-blind, controlled trial.

Authors:  Jacqueline Blommers; Elisabeth S m de Lange-De Klerk; Dirk J Kuik; Pieter D Bezemer; Sybren Meijer
Journal:  Am J Obstet Gynecol       Date:  2002-11       Impact factor: 8.661

4.  Comparison of tamoxifen with danazol for treatment of cyclical mastalgia.

Authors:  E Kontostolis; K Stefanidis; I Navrozoglou; D Lolis
Journal:  Gynecol Endocrinol       Date:  1997-12       Impact factor: 2.260

5.  Symptomatic treatment of premenstrual mastalgia in premenopausal women with lisuride maleate: a double-blind placebo-controlled randomized study.

Authors:  S Kaleli; Y Aydin; C T Erel; U Colgar
Journal:  Fertil Steril       Date:  2001-04       Impact factor: 7.329

6.  A randomized multicenter study of gamolenic acid (Efamast) with and without antioxidant vitamins and minerals in the management of mastalgia.

Authors:  Amit Goyal; Robert E Mansel
Journal:  Breast J       Date:  2005 Jan-Feb       Impact factor: 2.431

7.  Effects of tibolone on the breast.

Authors:  N Colacurci; D Mele; P De Franciscis; V Costa; N Fortunato; L De Seta
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  1998-10       Impact factor: 2.435

Review 8.  Overview of the main outcomes in breast-cancer prevention trials.

Authors:  J Cuzick; T Powles; U Veronesi; J Forbes; R Edwards; S Ashley; P Boyle
Journal:  Lancet       Date:  2003-01-25       Impact factor: 79.321

9.  Efficacy of topical nonsteroidal antiinflammatory drugs in mastalgia treatment.

Authors:  Tahsin Colak; Turgut Ipek; Arzu Kanik; Zekai Ogetman; Suha Aydin
Journal:  J Am Coll Surg       Date:  2003-04       Impact factor: 6.113

10.  Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity.

Authors:  C Harding; O Osundeko; L Tetlow; E B Faragher; A Howell; N J Bundred
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.